Published on November 11, 2009 at 3:19 AM
NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced that it received a $100,000 investment from the Epilepsy Therapy Project.
The Epilepsy Therapy Project invests in promising research efforts in order to help make new therapies a reality for patients, and the investment in NTP is one of the largest made in its history. “Our Board and our scientific advisors are enthusiastic about NTP and its lead compound. We view NTP’s development effort as a potentially important new therapy with a novel mechanism of action for millions of people living with uncontrolled epilepsy,” said Warren Lammert, Chairman and Co-Founder of the Epilepsy Therapy Project and epilepsy.com.
“We are honored that the Epilepsy Therapy Project has made such a substantial investment in our technology in order to help bring this new class of therapy to people with epilepsy, their families and clinicians. The Epilepsy Therapy Project’s Board of Directors and Scientific Advisory Board are comprised of some of the most influential thought leaders in the space who have dedicated their lives to developing new therapies in this area of significant unmet need. We greatly appreciate their support and are honored to receive such an endorsement of our work,” said Dr. Stephen D. Collins, Chief Executive Officer of NeuroTherapeutics Pharma.
Source: NeuroTherapeutics Pharma